ArticleAMB Express2025
Antibacterial, antibiofilm and cytotoxic activity of synthesized metal-incorporated mesoporous silica nanoparticles.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns.Drug delivery · 2026Review
- Smart Mesoporous Silica Nanoparticle-Based Drug Delivery Systems: Recent Advances in Biomedical Applications, Wound Healing and Therapeutic Perspectives.Pharmaceutics · 2026Review
- Camellia sinensis-synthesized silver nanoparticles and meropenem combination against extensively drug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Engineering Mesoporous Silica Hosts for Ultrasmall ZnO Nanoparticles: A Dendritic Polymer-Assisted Strategy Towards Sustainable, Safe, and Effective Antibacterial Systems.Nanomaterials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic misuse has triggered a global health crisis due to the rise of antimicrobial-resistant microorganisms. Recent studies suggest that nanoparticles (NPs), particularly silver nanoparticles, may provide a solution. However, their toxicity necessitates the development of novel carriers to enhance targeting while minimizing cytotoxicity. This study aimed to synthesize, characterize mesoporous silica nanoparticles (MSN) incorporated with silver alone or combined with zinc, and evaluate their antibacterial, antibiofilm, and cytotoxic properties. Characterization through X-ray diffraction (XRD) and scanning electron microscopy (SEM), revealed particle sizes between 413 and 560 nm. Antibacterial activity was assessed via the broth-dilution method against Staphylococcus aureus ATCC 25,923, Escherichia coli ATCC 25,922, Methicillin-resistant Staphylococcus aureus (MRSA) ATCC 33,591, and five multidrug-resistant pathogens (MDR). Two types of silver-incorporated mesoporous silica nanoparticles were synthesized: Ag/MCM-48 (10 mmol Ag) and Ag/Zn/MCM-48 (10 mmol Ag + 10 mmol Zn). The minimum inhibitory and minimum bactericidal concentrations ranged from 7.8 to 31.25 and 7.8 to 62.5 µg/mL, respectively. Ag/MCM-48 NPs exhibited 78% antibiofilm activity against MRSA ATCC 33,591, while Ag/Zn/MCM-48 NPs displayed up to 90% antibiofilm activity against MDR bacteria. Cytotoxicity assays revealed promising results, with CC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.